In this video, Adam Cohen, MD, University of Pennsylvania, Philadelphia, PA, gives an update on cohort C from the CARTITUDE-2 trial (NCT04133636), which is evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients after exposure to a BCMA-targeting antibody-drug conjugate (ADC). Dr Cohen comments on the response rate observed, the duration of response, and the safety profile of cilta-cel in these patients, and future outlooks. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.